购物车
- 全部删除
- 您的购物车当前为空
α-Glucosidase-IN-21 (Compound 2B) is a highly potent and orally bioavailable inhibitor of α-glucosidase. With an impressive IC50 value of 2.62 μM, this compound exhibits remarkable anti-diabetic properties [1].
α-Glucosidase-IN-21 (Compound 2B) is a highly potent and orally bioavailable inhibitor of α-glucosidase. With an impressive IC50 value of 2.62 μM, this compound exhibits remarkable anti-diabetic properties [1].
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | |
50 mg | ¥ 13,800 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | α-Glucosidase-IN-21 (Compound 2B) is a highly potent and orally bioavailable inhibitor of α-glucosidase. With an impressive IC50 value of 2.62 μM, this compound exhibits remarkable anti-diabetic properties [1]. |
体内活性 | α-Glucosidase-IN-21 (Compound 2B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin -induced diabetic rats [1]. α-Glucosidase-IN-21 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats [1]. α-Glucosidase-IN-21 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice [1]. Animal Model: Male Wistar albino rats (170-200 g), Streptozotocin-induced diabetes model [1] Dosage: 10 and 20 mg/kg Administration: Oral administration; daily, for 4 weeks Result: Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers. |
分子量 | 389.51 |
分子式 | C24H23NO2S |
CAS No. | 321686-01-5 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容